A lower weight after GLP-1 treatment does not tell you, by itself, whether insurance will continue paying. The relevant question is how your current plan evaluates continuation of therapy, using the original treatment history and the response since treatment began. Starting eligibility, renewal eligibility, the prescription itself, and the pharmacy claim are separate decisions. Ask for the actual continuation criteria rather than assuming that a BMI change automatically ends coverage—or automatically guarantees it.
The initial prior-authorization guide explains why a prescription may need an insurer review before payment. This article begins later: treatment is already under way and an approval period is approaching its end. The practical problem is assembling the right history while there is still time for the clinical team to review it. It is not a strategy for changing diagnoses, omitting inconvenient information, or making a successful treatment look unsuccessful.
Find the end date of the actual approval
Begin with the insurer or pharmacy-benefit administrator and the written approval notice. Confirm the member identification used, exact medicine and presentation, covered indication, authorization dates, and whether the document describes an initial or continuation approval. A portal showing an active prescription may not display the separate authorization period. Ask which document the pharmacy relies on when it submits the next claim.
Novo Nordisk professional guidance notes that some plans require reauthorization at six- or twelve-month intervals and that updated information may be needed. That is an example of variation, not a promise about the length of your own approval. A different plan, indication, or product presentation may use a different process. The useful date is the one on the actual approval and the current benefit rule.[1]
Keep the original baseline and the current record
A continuation assessment needs a timeline. Ask the original prescriber for the record from before treatment, including the relevant diagnosis, height and weight measurements, prior treatment history, and the plan under which medication began. Also keep more recent progress notes, treatment dates, tolerability discussions, and current measurements. A recent weight alone can describe where someone is now without explaining why long-term treatment started.
This is a records question, not permission to reuse a stale measurement as though it were current. Label the dates. If a new clinic asks for current information, provide it alongside the baseline rather than substituting the old number. Ask the clinical team to explain the distinction in the submission. If the baseline is missing, say so and request the original record; do not reconstruct a higher starting weight from memory simply because it might help a form pass.
One published program shows why indications matter
Wisconsin ForwardHealth publishes separate clinical requirements for initial and renewal Wegovy requests, with different eligible indications and age groups. Its cardiovascular-risk renewal section, for example, asks for continued diet and activity measures, current records, and adherence to the prescribed regimen. Its adolescent weight-management criteria are a separate section, including a comparison with the pretreatment BMI. A rule from one section cannot be transferred to every person taking the brand.[2]
The lesson is to read the heading before the threshold. A criterion may apply to a particular Medicaid program, a cardiovascular indication, an age group, an injection rather than a tablet, or an initial approval rather than renewal. A screenshot listing one percentage or a story about someone else receiving another year is not an adequate substitute. This guide does not assign your diagnosis to a different benefit category or establish that an indication is covered by your plan.
Ask who will prepare the clinical submission
A patient can request the current criteria and obtain records, but the treating professional needs to decide what the clinical submission should say. Ask the practice who receives renewal requests, whether an appointment is needed, where to send the approval notice, and how to check that the request was received. Those are workflow questions worth asking before the last fill, particularly when an insurer or employer has changed administrators.
For a new clinical service, separate the cost of arranging care from an assurance about payment for medication. The 9amHealth review and PlushCare review provide context for comparing service arrangements; neither link guarantees renewal success or means your insurer contracts with that service. Ask the selected practice specifically who handles continuation paperwork and whether the actual records can be reviewed before a new prescribing decision.
A new insurer may not inherit the old decision
Changing employers, plans, or pharmacy-benefit administrators can produce a new review even if the medicine has not changed. Supply the earlier approval as useful history, but ask whether it has any effect under the new benefit. The old authorization belongs to a defined coverage arrangement. It is not the same thing as a permanent entitlement to the drug across every future policy.
Marketplace consumer guidance recommends checking the new plan’s drug list and asking about its exception process when a needed prescription is not normally covered. That guidance does not mean every exclusion can be reversed or that a one-time refill must be available in every circumstance. Ask the plan to identify the precise obstacle: a clinical renewal requirement, a nonformulary product, an excluded benefit, a pharmacy-network rule, or an administrative mismatch.[3]
If the renewal is rejected, identify the reason
A pharmacy message saying authorization is required may mean no new request has arrived. A written clinical denial means a decision has been made. An expired membership record or a wrong product code is another problem again. Before gathering a large appeal packet, ask whether there is a formal decision, its date, and the stated reason. Keep the notice because the next step depends on what was actually decided.
Our appeals-and-denials guide covers review routes and their limits. Renewal preparation is narrower: make sure the right rule and complete, accurate history reach the right team. If the decision cites missing information, ask the prescriber whether that information exists and whether it was supplied. If it cites a benefit exclusion, ask for the applicable policy language. Those are different questions and should not be answered with the same generic appeal letter.
Check continuity before changing clinics
If you are moving to a different prescriber, ask which practice will take responsibility for the renewal already in progress. Two offices assuming the other is handling it can be more disruptive than a clearly assigned delay. Request confirmation of the handoff and retain the existing practice’s contact information until the receiving team confirms what it needs. Sending a portal message to a new service is not the same as having a clinician accept ongoing care.
The same distinction matters for clinical measurements. A renewal form might ask for recent data, while the most useful original evidence sits in another practice’s chart. Give the receiving team permission to explain what it can verify and what it cannot. If it requires a new assessment, ask about the clinical and financial implications before canceling the existing arrangement. A convenient price or intake appointment does not establish that all renewal documentation has transferred.
Keep administrative expectations realistic. An organized patient can reduce missing information, but cannot make every review immediate. The practical aim is to surface uncertainty before an avoidable last-minute problem: an unsigned form, the wrong member number, an absent baseline, or an appointment nobody realized was required. A reminder in your own calendar can complement the practice’s process while keeping the clinical judgment with the prescriber.
Plan for a possible gap without inventing a dosing plan
When a delay looks likely, tell the prescriber while there is still time to discuss it. State how much prescribed supply remains and whether there have already been missed doses. The clinical team can address what an interruption means for the specific product and patient. Do not stretch a prescription by splitting doses, changing intervals, borrowing another person’s medication, or treating a lower-priced compounded product as an automatic equivalent.
The missed-dose article describes why product-specific instructions matter. The maintenance-cost guide addresses the separate financial question. Paying cash for a fill may change the immediate transaction, but it does not settle future reimbursement, deductible credit, or a later renewal. Ask for those answers before assuming an insurer will repay a purchase made while the request is pending.
Make the paperwork useful to the next reviewer
Keep a compact folder with the approval notice, the exact current criterion or form, the baseline record, recent clinical notes, pharmacy messages, and the dated decision if one arrives. A brief cover sheet can list what each document shows and which dates it covers. Avoid replacing original records with a self-written summary; the summary should help the clinical team find the supporting material, not impersonate a clinician’s assessment.
If the treatment has worked, describe that accurately. If side effects, an interruption, or an inconsistent supply affected the response, tell the prescriber. A continuation decision should be based on the actual course, including its limitations. An orderly record makes a factual explanation easier, but it cannot promise approval. Coverage terms can change, and a well-supported request can still face a plan-specific restriction.
Questions to settle before the next review date
Ask when the current approval ends, whether the plan requires a continuation form, what original and current information it requests, and who will submit it. Ask how you will know the request is complete and whether the clinical team needs a visit to update the record. Write down a date to check progress rather than relying on an automatic reminder that may belong to the old insurer or an earlier pharmacy.
Finally, confirm what remains unresolved after an approval arrives. The dispensing pharmacy still needs to process the claim under the active benefit and check the selected presentation, network, and supply period. Our insurance-versus-cash-pay guide explains why approval and the final bill can differ. The objective is a coherent continuation record and a usable plan for the next fill—not an isolated approval screenshot whose conditions nobody has checked.